The only thing as ridiculous as your post is your name. Posts that make no mention of the science behind the trial are useless. You obviously do not comprehend the science, so you bet on % of other cancer trial successes. Well, short away, as a fool and his money soon part.
Exactly. It's easy to forget Stine & Co funded this entire operation long before immunotherapy / IDO was well known. They had a plan backed with real money and real experts. Selling out with the first success in an otherwise deep pipeline would surprise me - I think Stine gets a kick out of marching to his own drum when he feels he has the upper hand. Anybody care to elaborate how & why they licensed rVSV?
As always your posts are to the point. Based on the original log rank analysis used for this trial, if the alternative you describe above was accepted, how large of an increase in success would be expected? And, would there ever be an even ranking of these two approaches given a point in time? I was never comfortable with the complex nature of the log rank analysis - it takes a conservative approach to an extreme in my limited understanding.